A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to see how useful, safe, and tolerable an investigational drug called
ENMD-2076 is in treating patients with ovarian clear cell carcinomas.
ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A and tyrosine
kinase from working. These enzymes are needed for cells to divide including cancer cells.
ENMD-2076 also works by stopping the growth of new blood vessels which would provide the
tumor with nutrients for it to grow. It is believed that by blocking Aurora A and tyrosine
kinase enzymes from working and stopping new blood vessels from growing, the tumors may stop
growing or shrink.